Cornerstone Pharmaceuticals, Inc.

Rafael Pharmaceuticals, Inc. ’s lead candidate, devimistat, has hit the buffers in two Phase III trials. It has missed the primary endpoint in a Phase III study for first-line metastatic pancreatic ca

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. PanOptica Confirms Deal With Zhaoke For

Since 2017, nine new drugs have been approved for acute myeloid leukemia (AML) in the US, dramatically changing the treatment landscape, with the condition benefiting from breakthroughs in the underst

The US Federal Trade Commission once again was sharply divided on a pharma merger, voting 3-2 to permit AbbVie Inc. 's $63bn acquisition of Allergan PLC to go forward on the condition that they div